by Salvador Solis | Jan 11, 2023 | Uncategorized
OVERLAND PARK, KS; January 10, 2023—(BUSINESS WIRE) Dr. Vince Clinical Research (DVCR), an early phase CRO specializing in Phase 1 trials, announced that it has administered the first dose of Aclaris Therapeutics’ ATI-2138, in a Phase 1 multiple ascending...
by enewman | Dec 9, 2022 | Uncategorized
OVERLAND PARK, KS, December 12, 2022 (Globe Newswire) – Dr. Vince Clinical Research (DVCR) announced the addition of highly experienced investigator George J. Atiee, M.D. to the medical team at its world-class clinical pharmacology unit. Dr. Atiee has been...
by enewman | Nov 8, 2022 | Uncategorized
OVERLAND PARK, Kan.; November 8, 2022 (ACCESSWIRE) – Dr. Vince Clinical Research (DVCR), a world-class early phase contract research organization (CRO) specializing in the conduct of Phase I clinical trials, today announced that it has administered the first dose in...
by Salvador Solis | Nov 2, 2022 | Uncategorized
Study Conducted by Dr. Vince Clinical Research KANSAS CITY, Kan., Nov. 01, 2022 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and...
by enewman | Sep 21, 2022 | Uncategorized
OVERLAND PARK, Kan.–(BUSINESS WIRE)–Dr. Vince Clinical Research (DVCR), today announced the launch of its new, world-class clinical pharmacology unit and headquarters in Overland Park, Kansas. The custom-built, green-inspired research complex was...
by enewman | Sep 17, 2022 | Uncategorized
PRINCETON, N.J. & OVERLAND PARK, Kan.–(BUSINESS WIRE)–WCG, the world’s leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced the expansion of its Phase I review services, providing...
Recent Comments